Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Abstract Background Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory o...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B. Krasa, Dorothee Oberdhan, Ancilla W. Fernandes
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2023-06-01
Schriftenreihe:	BMC Nephrology
Schlagworte:	Autosomal dominant polycystic kidney disease (ADPKD) Tolvaptan Glomerular filtration rate Kidney volume Clinical trial Treatment
Online-Zugang:	https://doi.org/10.1186/s12882-023-03247-6
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!